Mersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Year End 2020 Financial Results and Business Updat...
February 19 2021 - 8:00AM
Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage
biopharmaceutical company focused on discovering and developing a
pipeline of antibody-drug conjugates (ADCs) targeting cancers in
areas of high unmet medical need, today announced that it will host
a conference call and webcast on Friday, February 26, 2021 at 8:00
a.m. ET to report financial results for the fourth quarter and year
ended December 31, 2020 and provide business updates.
To access the call, please dial 877-303-9226
(domestic) or 409-981-0870 (international) and provide the
Conference ID 2354447. A live webcast of the presentation will be
available on the Investors & Media section of the Mersana
website at www.mersana.com.
About Mersana TherapeuticsMersana Therapeutics
is a clinical-stage biopharmaceutical company using its
differentiated and proprietary ADC platforms to rapidly develop
novel ADCs with optimal efficacy, safety and tolerability to
meaningfully improve the lives of people fighting cancer. Mersana’s
lead product candidate, upifitamab rilsodotin (XMT-1536, UpRi), is
in the expansion portion of a Phase 1 proof-of-concept clinical
study in patients with ovarian cancer and NSCLC adenocarcinoma.
XMT-1592, Mersana’s second ADC product candidate targeting
NaPi2b-expressing tumors, was created using Mersana’s customizable
and homogeneous Dolasynthen platform and is in the dose escalation
portion of a Phase 1 proof-of-concept clinical study. The Company’s
early-stage programs include XMT-1660, a Dolasynthen ADC targeting
B7-H4, as well as XMT-2056, a STING-agonist ADC developed using the
Company’s Immunosynthen platform. In addition, multiple partners
are using Mersana’s Dolaflexin platform to advance their ADC
pipelines.
Contact:
Investor & Media ContactSarah Carmody,
617-844-8577scarmody@mersana.com
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Apr 2023 to Apr 2024